Acknowledgement
This study was supported by the Fund of the Biomedical Research Institute, Jeonbuk National University Hospital (2022). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding organizations. The funding organizations had no role in the design, preparation, review, or approval of this paper.
References
- Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395:1607-8. https://doi.org/10.1016/S0140-6736(20)31094-1
- Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med 2020;383:347-58. https://doi.org/10.1056/NEJMoa2021756
- Sobh A, Mosa DM, Khaled N, Korkor MS, Noureldin MA, Eita AM, et al. How multisystem inflammatory syndrome in children discriminated from Kawasaki disease: a differentiating score based on an inception cohort study. Clin Rheumatol 2023;42:1151-61. https://doi.org/10.1007/s10067-022-06444-0
- Giacalone M, Scheier E, Shavit I. Multisystem inflammatory syndrome in children (MIS-C): a mini-review. Int J Emerg Med 2021;14:50.
- National Institutes of Health. Therapeutic management of hospitalized pediatric patients with multisystem inflammatory syndrome in children (MIS-C) (with discussion on multisystem inflammatory syndrome in adults [MIS-A]) [Internet]. Bethesda: National Institutes of Health; 2022 [cited 2022 Dec 3]. Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-children/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/.
- Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol 2014;20:16014-9. https://doi.org/10.3748/wjg.v20.i43.16014
- Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 2013;5:79-99. https://doi.org/10.2147/DHPS.S28801
- Koritala T, Pattan V, Tirupathi R, Rabaan AA, Al Mutair A, Alhumaid S, et al. Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: a narrative review. Infez Med 2021;29:495-503.
- Kobayashi T, Fuse S, Sakamoto N, Mikami M, Ogawa S, Hamaoka K, et al. A new Z score curve of the coronary arterial internal diameter using the lambda-mu-sigma method in a pediatric population. J Am Soc Echocardiogr 2016;29:794-801.e29. https://doi.org/10.1016/j.echo.2016.03.017
- Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol 2020;72:1791-805. https://doi.org/10.1002/art.41454
- Kim H, Shim JY, Ko JH, Yang A, Shim JW, Kim DS, et al. Multisystem inflammatory syndrome in children related to COVID-19: the first case in Korea. J Korean Med Sci 2020;35:e391.
- Korea Disease Control and Prevention Agency (KDCA). COVID-19 antibody positive rate in Korea [Internet]. Cheongju: KDCA; 2022 [cited 2022 Nov 12]. Available from: https://www.kdca.go.kr/gallery.es?mid=a20509000000&bid=0007.
- World Health Organization (WHO). Multisystem inflammatory syndrome in children and adolescents with COVID-19 [Internet]. Geneva: WHO; 2020: [cited 2022 May 15]. Available from: https://apps.who.int/iris/bitstream/handle/10665/332095/WHO-2019-nCoV-Sci_Brief-Multisystem_Syndrome_Children-2020.1-eng.pdf ?sequence=1&isAllowed=y.
- Centers for Disease Control and Prevention (CDC). CSTE/CDC Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 infection surveillance case report from guidance, effective January 1, 2023 [Internet]. Atlanta: CDC; 2023 [cited 2023 May 4]. Available from: https://www.cdc.gov/mis/pdfs/MIS-C interim-case-reporting-guidance.pdf.
- Shana GC, Bobbi B, Jessica L, Matthew EO, Laura C, Joseph A, et al. COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep 2020;69:1074-80. https://doi.org/10.15585/mmwr.mm6932e2
- Choi SR, Kim K, Kim DS, Kang JM, Kim SJ, Kim JM, et al. Changes in cytomegalovirus seroprevalence in Korea for 21 years: a single center study. Pediatr Infect Vaccine 2018;25:123-31. https://doi.org/10.14776/piv.2018.25.e8
- Chou S. Newer methods for diagnosis of cytomegalovirus infection. Rev Infect Dis 1990;12 Suppl 7:S727-36. https://doi.org/10.1093/clinids/12.Supplement_7.S727
- Vella LA, Rowley AH. Current insights into the pathophysiology of multisystem inflammatory syndrome in children. Curr Pediatr Rep 2021;9:83-92. https://doi.org/10.1007/s40124-021-00257-6
- Yamaguchi Y, Takasawa K, Irabu H, Hiratoko K, Ichigi Y, Hirata K, et al. Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child. J Infect Chemother 2022;28:814-8. https://doi.org/10.1016/j.jiac.2022.01.011
- Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44. https://doi.org/10.1001/jama.2009.146